- Trial aims to evaluate safety, tolerability, and immunogenicity of vaccine candidate
- First dose given today, in Lusaka, Zambia
- Vaccine aims to combat numerous HIV strains, a key requirement of any vaccine to end the HIV/AIDs epidemic
With the first dose given at the Center for Family Health Research in Zambia (CFHRZ), in Lusaka, Zambia, the trial will extend to sites in Kenya and Uganda in the coming weeks.
Dr. William Kilembe, project director of CFHRZ and trial principal investigator, said: ‘International partnerships are crucial in developing and evaluating HIV vaccine candidates in countries and communities where HIV vaccines will ultimately have the greatest public health impact.